Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics

Cystic fibrosis is realizing the promise of personalized medicine. Recent advances in drug development that target the causal CFTR directly result in lung function improvement, but variability in response is demanding better prediction of outcomes to improve management decisions. The genetic modifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Strug, Lisa J., Gonska, Tanja, He, Gengming, Keenan, Katherine, Ip, Wan, Boëlle, Pierre-Yves, Lin, Fan, Panjwani, Naim, Gong, Jiafen, Li, Weili, Soave, David, Xiao, Bowei, Tullis, Elizabeth, Rabin, Harvey, Parkins, Michael D., Price, April, Zuberbuhler, Peter C., Corvol, Harriet, Ratjen, Felix, Sun, Lei, Bear, Christine E., Rommens, Johanna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Association Studies Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886039/
https://www.ncbi.nlm.nih.gov/pubmed/28171547
http://dx.doi.org/10.1093/hmg/ddw290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886039/
https://www.ncbi.nlm.nih.gov/pubmed/28171547
http://dx.doi.org/10.1093/hmg/ddw290

Ejemplares similares